Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the eastern cooperative oncology group 4599 study: Results of an exploratory analysis

Journal of Thoracic Oncology

Volumn 7, Issue 11, 2012, Pages 1707-1712

  Lopez Chavez, Ariel ^a   Young, Todd ^b   Fages, Sophie ^b   Leon, Larry ^b   Schiller, Joan H ^c   Dowlati, Afshin ^d   Brahmer, Julie R ^e   Johnson, David H ^c   Sandler, Alan ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMBOLISM; EXPLORATORY RESEARCH; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INFECTION; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; THROMBOSIS; TREATMENT OUTCOME;

EID: 84867900893     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318265b500     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009;6:206-217.
4. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-934.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
6. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothe-lial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
7. Borgström P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
8. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond frst progression is associated with prolonged overall survival in meta-static colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
9. Burger RA, Brady MF, Bookman MA, et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-2483.
10. Kosty M P, et al. Use of bevacizumab (bv) after induction therapy is associated with survival beneft in patients (pts) with non-small cell lung cancer (NSCLC) in the ARIES Observational Cohort Study (OCS) in 34th ESMO Congress. 2011.
11. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
12. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
13. Miller VA, et al. a randomized, double-blind, placebo-controlled, phase iiib trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for frst-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2009;27:LBA8002.
14. Kabbinavar FF, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for frst-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2010;28 15 Suppl:7526.
15. Pavlakis N, et al. MO19390 (SAiL) Study Group: safety of bevacizumab (Bv)-based therapy as frst-line treatment of eligible non-small-cell lung cancer (NSCLC) patients (pts) in 33rd ESMO Congress. 2010.
16. Dansin E, et al. Final safety data from patients who received maintenance bevacizumab in the SAiL trial (MO19390): frst-line bevacizumab plus chemotherapy in advanced or recurrent non-small cell lung cancer (NSCLC) in ESMO 2010. 2010.
17. Ferrara N, Hillan KJ, Gerber H P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
18. Morgensztern D, Govindan R. Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. Expert Rev Anticancer Ther 2006;6:545-551.
19. Brodowicz T, Krzakowski M, Zwitter M, et al.; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine frst-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163.
20. Fidias PM, et al. Phase iii study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
21. Zhang X, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer. Chest 2011;140:117-126.
22. Novello S, Milella M, Tiseo M, et al. Maintenance therapy in NSCLC: why? To whom? Which agent? J Exp Clin Cancer Res 2011;30:50.
23. Maemondo M, et al. Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Eng J Med 2010;362:2380-2388.
24. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Geftinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
25. Paz-Ares LG, et al. PARAMOUNT: phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous on-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2011;29 18 Suppl:CRA7510.
26. Barlesi F, et al. AVAPERL (MO22089): fnal effcacy outcomes for patients with advanced non-squamous non-small cell lung cancer (ns NSCLC) randomized to continuation maintenance (mtc) with beva-cizumab (bev) or bev+pemetrexed (pem) after frst-line (1L) bev-cis-platin (cis)-pem treatment (Tx). European Multidisciplinary Cancer Congress, 2011.
27. Dahlberg SE, et al. A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevaci-zumab and pemetrexed (BPm) following carboplatin, paclitaxel and bev-acizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). ASCO Meeting Abstracts 2011;29 15 Suppl:TPS218.
28. Patel JD, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase iii study of pemetrexed/carbo-platin/ bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bev-acizumab in patients with stage iiib or iv nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252-256.